| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
| Share Statistics | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.8 | $565.8 | 9% |
|
| Shares Out (Mil) | 26.2 | 42.5 | 34% |
|
| Institutional Ownership | 72.7% | 83.9% | 44% |
|
| Float (Mil) | 27.0 | 45.7 | 34% |
|
| Beta | 0.99 | 0.72 | 60% |
|
| Avg Daily Volume (000s) | 182 | 402 | 41% |
|
| Price Change (52-week) |
(51.6%) | 61.7% | 17% |
|
| Growth | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (16.4%) | (1.4%) | 24% |
|
| EPS (5yr) | 21.3% | 15.1% | 70 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (52.7%) | (15.0%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.410) | ($2.030) | ($1.440) | |
| Month Ago EPS | ($0.410) | ($2.030) | ($1.440) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.250) | ($1.870) | ($0.810) | |
| Year/Year Chg | 20.9% | (40.0%) | (80.2%) | |
| Financials | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $317 | 7% |
|
| Net Income (TTM) (Mil) | ($46) | ($11) | 17% |
|
| EPS (TTM) | ($2.122) | ($0.700) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($7) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $11 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | $16 | $493 | 10% |
|
| Valuation | CTXR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.24 | 2.40 | 4% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.3% | 69.4% | 87% |
|
| Net Margin | (651.3%) | 2.0% | 1% |
|
| ROA | (34.3%) | (22.2%) | 15% |
|
| ROE | (70.3%) | (22.8%) | 12% |
|
| Liabilities to Assets | 46.6% | 32.5% | 38% |
|
| F-Score | 3 | 3 | 18% |
|
Citius Pharmaceuticals, Inc. did not pass any screens on 9/25/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
